Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Inmune Bio ( (INMB) ) has provided an update.
On February 6, 2025, INmune Bio entered a license agreement with Great Ormond Street Hospital NHS Foundation Trust for exclusive commercial use of clinical trial data from the Mission EB study, which investigates CORDStrom’s efficacy in treating pediatric RDEB. This agreement allows INmune Bio to prepare applications for marketing authorization in the US and Europe. The company will provide CORDStrom to UK patients enrolled in ongoing studies and pay milestone fees upon receiving the first marketing authorization. Additionally, INmune Bio announced the termination of its Loan Agreement with Silicon Valley Bank without penalties. The Mission EB study demonstrated CORDStrom’s potential in treating RDEB, leading to plans for filing a Biologics License Application with the FDA and similar applications in Europe. CORDStrom has been granted Rare Pediatric Disease and Orphan Drug designations by the FDA, enhancing its market potential and support for further development.
More about Inmune Bio
INmune Bio, Inc. is a clinical-stage company focused on developing treatments that harness the patient’s innate immune system to combat diseases, primarily in the inflammation and immunology sectors. The company is actively involved in creating innovative therapies using its patent-pending CORDStrom platform, which utilizes mesenchymal stromal cells for treating complex inflammatory diseases, including rare pediatric conditions like recessive dystrophic epidermolysis bullosa (RDEB).
YTD Price Performance: 94.62%
Average Trading Volume: 330,582
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $212.7M
See more insights into INMB stock on TipRanks’ Stock Analysis page.
